Open access · OA
via OpenAlex
A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes: Developing topics
Valentina Rose Garbarino, Sydney Tran, Jordan E Glassman, James L. Kirkland, Nicolas Musi, Sudha S. Seshadri, Miranda E. Orr
Alzheimer s & Dementia · 2020 · ▲ 9 citations
Abstract
Abstract Background Senescent cells accumulate with advanced age and contribute to dysfunction and disability. We recently discovered that tau protein accumulation induces cellular senescence(definition) in Alzheimer’s disease and other tauopathies, a group of brain diseases characterized by the deposition of tau protein (Musi et al., 2018). Treating mice with senolytics(definition), drugs that specifically target senescent cells for their removal, reduced pathology and improved brain structure and function in tauopathy mice. Our initial study focused on dasatinib plus quercetin (D+Q). We now report results from directly comparing D+Q to fisetin (FIS) to determine differences in efficacy, toxicity, and sex and genotype as we work to translate this therapy to clinical studies. Method Fourteen‐month old male and female wild type (WT) and tau transgenic (rTg4510) mice were treated intermittently (3 days on, 11 days off, for 6 cycles) with D+Q, FIS, or vehicle by oral gavage. Physical and behavioral outcomes were measured before and after treatment. Result Both senolytic therapies significantly enhanced female rTg4510 mouse performance in the y‐maze (increased preference for novel arm (p = 0.00093 and p = 0.0015, D+Q and FIS, respectively); no treatment changes were noted in WT females or male mice. Pre‐ and post‐treatment comparisons of body weight revealed that D+Q uniquely increased body weight in female mice (WT: p=0.0005 and t: p = 0.024). Similarly, body length was increased by D+Q in WT (p= 0.0012) and rTg4510 (p= 0.0457) females, and WT males (p= 0.0481). Physical performance measures included run speed whereby D+Q increased WT female (p= 0.0002) and male (p=0.0267) velocity. FIS only affected WT males (p= 0.0022) but not females; and rTg4510 male (p=0.0015) but not female mice. Additional genotype, sex and treatment specific effects were observed in measures of frailty, grip strength, stride length, and nerve conduction. Our on‐going analyses of brain volumetry changes (MRI), axon integrity, transcriptomics, tau pathology, and inflammatory changes among the groups will provide mechanistic insights responsible for these behavioral phenotypes. Conclusion Our study suggests that tailoring senolytic therapies to specific individuals based on sex and disease state may provide the most benefit as we translate this promising therapy to clinical use.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/alz.047607
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Garbarino, V.R., Tran, S., Glassman, J.E., Kirkland, J.L., Musi, N., Seshadri, S.S., & Orr, M.E. (2020). A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes: Developing topics. <em>Alzheimer s & Dementia</em>. https://doi.org/10.1002/alz.047607
Vancouver
Garbarino VR, Tran S, Glassman JE, Kirkland JL, Musi N, Seshadri SS, et al. A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes: Developing topics. Alzheimer s & Dementia. 2020. doi:10.1002/alz.047607.
BibTeX
@article{valentina2020Aheadt,
title = {A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes: Developing topics},
author = {Valentina Rose Garbarino and Sydney Tran and Jordan E Glassman and James L. Kirkland and Nicolas Musi and Sudha S. Seshadri and Miranda E. Orr},
journal = {Alzheimer s & Dementia},
year = {2020},
doi = {10.1002/alz.047607},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s & Dementia 2025
Open access · CC-BY
Head‐to‐head comparison of two senolytic therapies in a mouse model of tauopathy
Innovation in Aging 2024
Open access · CC-BY
HIGH RESOLUTION SPATIAL PROTEOGENOMICS TO ASSESS TARGET ENGAGEMENT AND COMPARE SENOLYTIC EFFICACY IN THE BRAIN OF TAU TRANSGENIC MICE
Aging Cell 2025
Open access · CC-BY
Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches
Proteomes 2016
Open access · CC-BY
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease
Aging Cell 2018
Open access · CC-BY
Tau protein aggregation is associated with cellular senescence in the brain
Neurobiology of Disease 2024
Open access · CC-BY